-
Je něco špatně v tomto záznamu ?
The future of hybrid ablation: an emerging need for an anticoagulation protocol for thoracoscopic ablation
P. Osmancik, P. Budera
Jazyk angličtina Země Čína
Typ dokumentu úvodníky, komentáře, práce podpořená grantem
Grantová podpora
NV16-32478A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
PubMed
28449532
DOI
10.21037/jtd.2017.02.95
Knihovny.cz E-zdroje
- MeSH
- ablace * metody MeSH
- antikoagulancia * terapeutické užití MeSH
- cévní mozková příhoda prevence a kontrola MeSH
- chemoprofylaxe metody MeSH
- fibrilace síní chirurgie MeSH
- klinické protokoly MeSH
- lidé MeSH
- pooperační komplikace prevence a kontrola MeSH
- rizikové faktory kardiovaskulárních chorob MeSH
- torakoskopie metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- komentáře MeSH
- práce podpořená grantem MeSH
- úvodníky MeSH
The midterm efficacy of hybrid ablation of atrial fibrillation (AF) reported in recent papers is about 70% in terms of sinus rhythm maintenance without antiarrhythmic drugs. Bearing in mind that the majority of patients enrolled are patients with persistent and long-standing persistent AF, the reported efficacies seem to be very good. Despite the high efficacies, safety remains a critical issue in hybrid, and especially thoracoscopic ablations. The frequency of complications during thoracoscopic ablations is more than 10% in the majority of reports. Most are short-term with no sequelae (such as pneumothorax or pneumonia); however, life-threatening complications have also been described, e.g., a sternotomy in response to a laceration of the left atrium (LA). One of the most serious ablation complications is stroke. The rate of strokes, which has been reported during or shortly after thoracoscopic ablation, seems to be higher than the rate reported after catheter ablation. This is especially true in papers describing thoracoscopic ablations that were not immediately followed by a catheter ablation. A possible explanation is differences in anticoagulation management during the two procedures. During catheter endocardial procedures, a standard anticoagulation protocol exists and is routinely applied; however, there is no such set of recommendations for anticoagulation during the thoracoscopic-phase of an ablation. It seems probable that, in many cases, no anticoagulation is used during thoracoscopic ablations. Moreover, whatever anticoagulation protocol is used during thoracoscopic ablations often goes unreported. A discussion about the best anticoagulation strategy during thoracoscopic ablation is urgently needed. In the future, standards of anticoagulation during thoracoscopic ablation should be clearly reported, just as they are now for catheter ablations.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22007005
- 003
- CZ-PrNML
- 005
- 20230112092511.0
- 007
- ta
- 008
- 220223s2017 cc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21037/jtd.2017.02.95 $2 doi
- 035 __
- $a (PubMed)28449532
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a cc
- 100 1_
- $a Osmančík, Pavel, $u Cardiocenter, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic $d 1972- $7 xx0104796
- 245 14
- $a The future of hybrid ablation: an emerging need for an anticoagulation protocol for thoracoscopic ablation / $c P. Osmancik, P. Budera
- 520 9_
- $a The midterm efficacy of hybrid ablation of atrial fibrillation (AF) reported in recent papers is about 70% in terms of sinus rhythm maintenance without antiarrhythmic drugs. Bearing in mind that the majority of patients enrolled are patients with persistent and long-standing persistent AF, the reported efficacies seem to be very good. Despite the high efficacies, safety remains a critical issue in hybrid, and especially thoracoscopic ablations. The frequency of complications during thoracoscopic ablations is more than 10% in the majority of reports. Most are short-term with no sequelae (such as pneumothorax or pneumonia); however, life-threatening complications have also been described, e.g., a sternotomy in response to a laceration of the left atrium (LA). One of the most serious ablation complications is stroke. The rate of strokes, which has been reported during or shortly after thoracoscopic ablation, seems to be higher than the rate reported after catheter ablation. This is especially true in papers describing thoracoscopic ablations that were not immediately followed by a catheter ablation. A possible explanation is differences in anticoagulation management during the two procedures. During catheter endocardial procedures, a standard anticoagulation protocol exists and is routinely applied; however, there is no such set of recommendations for anticoagulation during the thoracoscopic-phase of an ablation. It seems probable that, in many cases, no anticoagulation is used during thoracoscopic ablations. Moreover, whatever anticoagulation protocol is used during thoracoscopic ablations often goes unreported. A discussion about the best anticoagulation strategy during thoracoscopic ablation is urgently needed. In the future, standards of anticoagulation during thoracoscopic ablation should be clearly reported, just as they are now for catheter ablations.
- 650 _7
- $a fibrilace síní $x chirurgie $7 D001281 $2 czmesh
- 650 17
- $a ablace $x metody $7 D055011 $2 czmesh
- 650 _7
- $a torakoskopie $x metody $7 D013906 $2 czmesh
- 650 _7
- $a pooperační komplikace $x prevence a kontrola $7 D011183 $2 czmesh
- 650 _7
- $a rizikové faktory kardiovaskulárních chorob $7 D000082742 $2 czmesh
- 650 _7
- $a cévní mozková příhoda $x prevence a kontrola $7 D020521 $2 czmesh
- 650 _7
- $a chemoprofylaxe $x metody $7 D018890 $2 czmesh
- 650 17
- $a antikoagulancia $x terapeutické užití $7 D000925 $2 czmesh
- 650 _7
- $a výsledek terapie $7 D016896 $2 czmesh
- 650 _7
- $a klinické protokoly $7 D002985 $2 czmesh
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 655 _2
- $a úvodníky $7 D016421
- 655 _2
- $a komentáře $7 D016420
- 655 _7
- $a práce podpořená grantem $7 D013485 $2 czmesh
- 700 1_
- $a Budera, Petr $u Clinic of Cardiac Surgery, University Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic $7 xx0270813
- 773 0_
- $w MED00194907 $t Journal of thoracic disease $x 2072-1439 $g Roč. 9, č. 3 (2017), s. E322-E326
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28449532 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220223 $b ABA008
- 991 __
- $a 20230112092504 $b ABA008
- 999 __
- $a kom $b bmc $g 1763185 $s 1158185
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 9 $c 3 $d E322-E326 $e - $i 2072-1439 $m Journal of thoracic disease $n J Thorac Dis $x MED00194907
- GRA __
- $a NV16-32478A $p MZ0
- LZP __
- $c NLK120 $d 20230111 $a 2021-granty